Altimmune, Inc.
ALT
$2.91
-$0.02-0.68%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 80.00% | 105.00% | -61.54% | -95.11% | -95.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 80.00% | 105.00% | -61.54% | -95.11% | -95.12% |
| Cost of Revenue | -12.76% | -19.21% | -14.56% | -6.79% | 9.32% |
| Gross Profit | 12.78% | 19.24% | 14.52% | 6.32% | -9.94% |
| SG&A Expenses | 39.31% | 34.02% | 12.22% | 10.07% | 14.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.28% | -8.39% | -9.12% | -3.38% | 10.41% |
| Operating Income | 1.30% | 8.42% | 9.09% | 2.99% | -10.90% |
| Income Before Tax | -0.18% | 6.61% | 18.28% | 12.75% | 1.99% |
| Income Tax Expenses | 100.00% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.93% | 7.33% | 18.94% | 13.42% | 2.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.93% | 7.33% | 18.94% | 13.42% | 2.72% |
| EBIT | 1.30% | 8.42% | 9.09% | 2.99% | -10.90% |
| EBITDA | 1.25% | 8.31% | 8.92% | 2.72% | -11.30% |
| EPS Basic | 25.18% | 24.14% | 31.25% | 27.25% | 21.09% |
| Normalized Basic EPS | 25.72% | 23.46% | 19.69% | 15.61% | 8.25% |
| EPS Diluted | 25.18% | 24.14% | 31.25% | 27.25% | 21.09% |
| Normalized Diluted EPS | 25.72% | 23.46% | 19.69% | 15.61% | 8.25% |
| Average Basic Shares Outstanding | 37.10% | 22.17% | 17.12% | 17.95% | 23.65% |
| Average Diluted Shares Outstanding | 37.10% | 22.17% | 17.12% | 17.95% | 23.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |